Search Result

Results for "

protein active sites

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (1) Amyloid-β (1) Antibiotic (5) Arp2/3 Complex (1) Bacterial (8) Beta-secretase (5) Biochemical Assay Reagents (8) CaMK (1) Caspase (1) CDK (1) Dipeptidyl Peptidase (1) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (2) Drug Metabolite (1) Elastase (1) Endogenous Metabolite (1) Epigenetic Reader Domain (1) ERK (1) FAP (2) Fluorescent Dye (1) HIV (1) HSP (2) Isotope-Labeled Compounds (3) Methylenetetrahydrofolate Dehydrogenase (MTHFD) (2) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) NO Synthase (1) p97 (1) Parasite (4) PDI (2) Penicillin-binding protein (PBP) (1) Phosphatase (1) PKA (1) PKC (1) Prion Protein (1) PROTACs (1) Reactive Oxygen Species (ROS) (1) Reference Standards (3) SARS-CoV (2) Sialyltransferase (1) Src (1) Virus Protease (2)
By Research Areas:	Cancer (22) Cardiovascular Disease (1) Infection (10) Inflammation/Immunology (3) Metabolic Disease (4) Neurological Disease (10)
Click Chemistry:	Alkynes (3)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1455

Clindamycin 10+ Cited Publications	Bacterial Antibiotic Parasite	Infection Cancer
Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit *bacterial protein* synthesis*, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus* at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .

HY-13240

LY2886721 2 Publications Verification	Beta-secretase	Neurological Disease
LY2886721 is a potent, selective and orally active *beta-site* amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC₅₀ of 20.3 nM for recombinant human BACE1. LY2886721 is selectivity against cathepsin D, pepsin, and renin, but lacking selectivity against BACE2 (IC₅₀** of 10.2 nM). LY2886721 can across blood-brain barrier and has the potential for Alzheimer's disease treatment .

HY-B2228

Proteinase, Aspergillus oryzae 1 Publications Verification	Biochemical Assay Reagents	Cancer
Proteinase, Aspergillus oryzae is a serine protease that hydrolyzes peptide bonds in protein substrates, preferring alkaline conditions (optimal pH 10.5). It efficiently degrades casein, poly-L-glutamic acid, and poly-L-lysine, with activity irreversibly inhibited by diisopropylfluorophosphate (DFP) and potato inhibitor. This enzyme catalyzes proteolysis via serine residues in its active site, finding applications in food processing (e.g., soy sauce fermentation), detergents, and leather industries due to its high yield in solid-state fermentation and cost-effective production.

HY-15908

BCA 5+ Cited Publications Disodium bicinchoninate	Beta-secretase	Neurological Disease Cancer
BCA (Disodium bicinchoninate) is an orally active and non-competitive *Beta-site* amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC₅₀ value of 28 µM, a K_i** value of 43 µM. BCA shows anticancer activity. BCA has the potential for the research of Alzheimer's disease (AD) .

HY-109052

Atabecestat 1 Publications Verification JNJ-54861911	Beta-secretase	Neurological Disease
Atabecestat (JNJ-54861911) is a potent brain-penetrant and orally active *β-site* amyloid precursor protein cleaving enzyme 1 (BACE1)** inhibitor, achieves robust and high CSF Aβ reduction. Atabecestat s tolerated and displays a sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat has the potential for Alzheimer's Disease treatment .

HY-100433

PACMA 31 5 Publications Verification	PDI	Cancer
PACMA 31 is an irreversible, orally active protein disulfide isomerase (PDI) inhibitor with an IC₅₀ of 10 μM. PACMA 31 forms a covalent bond with the active site cysteines of PDI. PACMA 31 shows tumor targeting ability and significantly suppresses ovarian tumor growth without causing toxicity to normal tissues . PACMA 31 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13032B

Molibresib besylate Maximum Cited Publications 21 Publications Verification GSK 525762C; I-BET 762 besylate	Epigenetic Reader Domain ERK	Cancer
Molibresib besylate (GSK 525762C; I-BET 762 besylate) is an orally active pan-BET inhibitor that targets and binds to BRD2, BRD3, BRD4 and BRDT. By competitively occupying acetylated lysine binding sites, Molibresib besylate disrupts the interaction between BET proteins and chromatin, thereby effectively inhibiting MYC expression and target gene transcription. Molibresib besylate exhibits broad antiproliferative activity, which not only inhibits cancer cell growth and induces growth arrest, but also downregulates mitosis-related genes and upregulates the level of p-ERK1/2. When combined with MEK inhibitors, Molibresib besylate shows a significant synergistic effect, reduces tumor burden in mouse models of leukemia, modulates the immune microenvironment and prolongs survival. Molibresib besylate is widely applicable to research related to acute myeloid leukemia, multiple myeloma, triple-negative breast cancer, small-cell lung cancer and various advanced refractory solid tumors .

HY-153552A

NH2-UAMC1110 TFA	FAP	Cancer
NH2-UAMC1110 TFA is an aminobutoxy derivative of the fibroblast activation protein (FAP) inhibitor UAMC1110 (HY-100684), and is a precursor compound for the synthesis of FAP inhibitor probes, not directly used in bioactivity experiments. For example, NH2-UAMC1110 TFA is involved in the synthesis of the radiotracer FAPI-QS, which exhibits high tumor selectivity and high dose effect, and has been used in tumor diagnosis. NH2-UAMC1110 TFA structurally incorporates an active amino group, allowing it to form covalent bonds with various molecules (such as DOTA, DATA5m, radionuclide chelators, etc.) to synthesize molecular imaging probes or targeted compounds with the ability to target FAP. NH2-UAMC1110 TFA specifically binds to the FAP active site, inhibiting its proline-selective serine protease activity (including dipeptidyl peptidase and endopeptidase activity), blocking FAP-mediated tissue remodeling-related processes. Its key activity is high targeting and high affinity, and its core function is to act as a targeting module coupled with bifunctional chelators (such as DOTA, DATA5m). NH2-UAMC1110 TFA can be applied to diagnostic imaging studies of tumors expressing FAP (such as colorectal cancer, pancreatic cancer, etc.), and also provides molecular tools for targeted research of FAP-related diseases with high FAP expression, such as fibrosis and arthritis .

HY-W998680

Fluorescein-maleimide 5-FITC-Maleimide	Fluorescent Dye	Others
Fluorescein-maleimide (5-FITC-Maleimide) is a thiol-reactive fluorescent derivatization reagent and non-specific protein labeling reagent. Fluorescein-maleimide covalently binds to protein thiol groups for protein labeling. Fluorescein-maleimide covalently binds to protein amino and imidazole groups under neutral pH conditions. Fluorescein-maleimide is used for fluorescent labeling of proteins, nucleic acids or other molecules containing one or more thiol groups (Ex/Em = 494/519 nm) .

HY-10393

Eperezolid PNU-100592	Bacterial Antibiotic	Infection
Eperezolid (PNU-100592) is an orally active protein synthesis inhibitor that targets the bacterial 50S ribosomal subunit. Eperezolid competitively binds to a specific site on the ribosomal 50S subunit (overlapping with the binding sites of chloramphenicol (HY-B0239) and lincomycin (HY-117660)) to inhibit the translation initiation stage and exert antibacterial activity. Eperezolid can induce host cell autophagy to enhance the clearance of intracellular mycobacteria, and its MIC₉₀ for Staphylococcus aureus and Enterococcus is 1-4 μg/mL. Eperezolid is mainly used for antibacterial research on infections with Gram-positive bacteria such as methicillin-resistant (HY-121544) Staphylococci and vancomycin-resistant (HY-B0671) Enterococci, as well as infections with intracellular bacteria such as Mycobacterium tuberculosis .

HY-131943

DS44960156	Methylenetetrahydrofolate Dehydrogenase (MTHFD)	Neurological Disease Cancer
DS44960156 is a selective MTHFD2 inhibitor with moderate to low blood-brain barrier penetration (IC₅₀=1.6 μM, K_i=1.23 μM). DS44960156 specifically binds to the active site of MTHFD2, disrupts redox homeostasis and blocks serine-mediated one-carbon metabolism, thereby increasing the NAD ⁺/NADH ratio and ROS levels. DS44960156 not only effectively inhibits the proliferation of glioma cells, but also enhances the sensitivity of cells to glutamine starvation-induced death. DS44960156 binds to plasma proteins, shows no mutagenicity, carcinogenicity or acute oral toxicity, and serves as a research agent for glioblastoma multiforme and other cancers .

HY-142035

N-Propargylglycine 1 Publications Verification	Mitochondrial Metabolism	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
N-Propargylglycine is a brain-penetrant and orally active PRODH inhibitor. N-Propargylglycine covalently modifies enzyme-bound FAD and active site lysine, causing enzyme structural distortion, protein decay, and irreversible inhibition of proline and 4-hydroxyproline catabolism. N-Propargylglycine induces UPRmt, upregulates mitochondrial chaperones and YME1L1, enhances mitochondrial proteostasis, blocks astrocytic L-proline consumption, and abolishes L-proline’s ATP-maintaining and viability-protective effects. N-Propargylglycine stimulates neural processes, increases brain proline, hydroxyproline, and sarcosine levels, partially normalizes Huntington’s disease whole brain transcriptomes. N-Propargylglycine reduces hyperoxaluria, prevents calcium oxalate stone formation, reduces kidney tubular damage, and restores weight and survival in Grhpr knockout mice. N-Propargylglycine can be used for the research of breast cancer, neurodegenerative disorders, Huntington’s disease, and primary hyperoxaluria type 2 .

HY-153552

NH2-UAMC1110	FAP	Cancer
NH2-UAMC1110 is an aminobutoxy derivative of the fibroblast activation protein (FAP) inhibitor UAMC1110 (HY-100684), and is a precursor compound for the synthesis of FAP inhibitor probes, not directly used in bioactivity experiments. For example, NH2-UAMC1110 is involved in the synthesis of the radiotracer FAPI-QS, which exhibits high tumor selectivity and high dose-response, and has been used for tumor diagnosis. NH2-UAMC1110 introduces an active amino group into its structure, enabling it to form covalent bonds with various molecules (such as DOTA, DATA5m, radionuclide chelators, etc.), thereby synthesizing molecular imaging probes or targeted compounds with the ability to target FAP. NH2-UAMC1110 specifically binds to the FAP active site, inhibiting its proline-selective serine protease activity (including dipeptidyl peptidase and endopeptidase activity), blocking FAP-mediated tissue remodeling processes. Its key activity is high targeting and high affinity, and its core function is to be coupled with bifunctional chelators (such as DOTA, DATA5m) as a targeting module. NH2-UAMC1110 can be applied to diagnostic imaging studies of tumors expressing FAP (such as colorectal cancer, pancreatic cancer, etc.), and also provides molecular tools for targeted research of FAP-related diseases with high FAP expression, such as fibrosis and arthritis .

HY-124832

δ-Secretase inhibitor 11 1 Publications Verification	Caspase Amyloid-β	Neurological Disease
δ-Secretase inhibitor 11 (compound 11) is an orally active, potent, BBB-penetrated, non-toxic, selective and specific δ-secretase inhibitor, with an IC₅₀ of 0.7 μM. δ-Secretase inhibitor 11 interacts with both the active site and allosteric site of δ-secretase. δ-Secretase inhibitor 11 attenuates tau and APP (amyloid precursor protein) cleavage. δ-Secretase inhibitor 11 ameliorates synaptic dysfunction and cognitive impairments in tau P301S and 5XFAD transgenic mouse models. δ-Secretase inhibitor 11 can be used for Alzheimer's disease research .

HY-P2463

Fequesetide	Arp2/3 Complex	Inflammation/Immunology
Fequesetide, a peptide segment, is the active site within the protein thymosin β₄ responsible for actin binding, cell migration and wound healing .

HY-115531

UNC-2170	DNA/RNA Synthesis	Cancer
UNC-2170 is a functionally active, fragment-like ligand for 53BP1 (IC₅₀=29 µM; K_d=22 µM). UNC-2170 shows at least 17-fold selectivity for 53BP1 as compared to nine other methyl-lysine (Kme) reader proteins. 53BP1 is a Kme binding protein that plays a central role in DNA Damage Repair (DDR) pathways and is recruited to sites of double-strand breaks (DSB) .

HY-W284558

Sodium hexadecyl sulfate	Biochemical Assay Reagents	Others
Sodium hexadecyl sulfate is a long-chain anionic surfactant. Sodium hexadecyl sulfate can act as an interface-regulating substance to form a soft layer on the surface of carbon nanotubes, guide proteins to adsorb in the correct orientation with active sites facing outward through electrostatic interactions, and significantly enhance the activity of immobilized enzymes. Sodium hexadecyl sulfate can replace or supplement SDS (HY-Y0316) in capillary gel electrophoresis (CGE) .

HY-161177

PROTAC SARS-CoV-2 3CLPro degrader 2	PROTACs SARS-CoV Virus Protease	Infection
PROTAC KRAS G12D degrader 2 is a peptidomimetic PROTAC specifically targeting the dimeric SARS-CoV-2 3CL ^Pro protein. PROTAC KRAS G12D degrader 2 inhibits SARS-CoV-2 3CLPro with an IC₅₀ of 21.2 μM. PROTAC KRAS G12D degrader 2 specifically binds to the active site of SARS-CoV-2 3CL ^Pro. PROTAC KRAS G12D degrader 2 reduces protein levels of SARS-CoV-2 3CL ^Pro without affecting cell viability. PROTAC KRAS G12D degrader 2 can be used for the study of viral infections in Coronavirus genera .

HY-W000854

3-Methoxybenzeneboronic acid 3-Methoxyphenylboronic acid	Biochemical Assay Reagents	Others
3-Methoxybenzeneboronic acid (3-Methoxyphenylboronic acid) is a boronic acid derivative. 3-Methoxybenzeneboronic acid shows best suitable binding pattern at the active site by interacting non-covalently with amino acid residues of proteins. 3-Methoxybenzeneboronic acid is a biochemical reagent that can be used as a biological material or organic compound for life science related research .

HY-B1455S1

Clindamycin-13C,d3	Isotope-Labeled Compounds Bacterial Antibiotic Parasite	Infection
Clindamycin- ¹³C,d₃ is the ¹³C- and deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .

HY-158615

STING18 Stimulator of interferon genes 18	Others	Others
STING18 (Stimulator of interferon genes 18) is a compound that inhibits STING protein by utilizing a small molecule active site dimer, with good oral exposure, slow binding kinetics, and functional inhibitory activity on STING-mediated cytokine release.

HY-D2956

BC-GLA-NHS CLIP-GLA-NHS	Biochemical Assay Reagents	Others
BC-GLA-NHS (CLIP-GLA-NHS) is a NHS-labeled CLIP tag, which is an amine-reactive crosslinker and can achieve site-specific protein labeling. The NHS ester of BC-GLA-NHS reacts with the primary amine of the target molecule (such as antibodies, quantum dots) in a pH 7.5-8.5 buffer solution to form a stable amide bond. After coupling, the BC molecule undergoes a nucleophilic substitution reaction with the active site (Cys) of the CLIP-tagged fusion protein, releasing benzylcytosine and forming an irreversible thioether bond, achieving covalent labeling. BC-GLA-NHS can be used for click chemistry labeling .

HY-163548

SPP-002	Sialyltransferase	Cancer
SPP-002 is a ST6GAL1 inhibitor with a human IC₅₀ of 16.7 μM. SPP-002 selectively inhibits N-glycan sialylation over O-glycan sialylation and binds strongly to the enzyme active site. SPP-002 suppresses expression of signaling proteins in the integrin/FAK/paxillin pathway. SPP-002 can be used for the research of triple negative breast cancer metastasis .

HY-P5525

AC3-I, myristoylated Autocamtide-3 Derived Inhibitory Peptide	CaMK	Others
AC3-I, myristoylated is a biological active peptide. (This is a myristoylated form of Autocamtide-3-Derived Inhibitory Peptide (AC3-I), a highly specific inhibitor of Calmodulin-Dependent Protein Kinase ll (CaMKII) that is resistant to proteolysis. AC3-I is derived from Autocamtide-3, a substrate for CaMKII, with the Thr-9 phosphorylation site substituted with Ala.)

HY-176001

DPP8/9-IN-1	Dipeptidyl Peptidase	Inflammation/Immunology Cancer
DPP8/9-IN-1 (Compound 16) is a selective covalent inhibitor of dipeptidyl peptidases 8 and 9 (DPP8/9) with IC₅₀ values of 14 and 298 nM, respectively. DPP8/9-IN-1 binds irreversibly to the active site serine (S730 in DPP9) via a phosphonate warhead and blocks substrate binding to inhibit DPP8/9-mediated protein processing. DPP8/9-IN-1 is promising for research of cancers and inflammatory diseases .

HY-174438

PSEC13	HSP	Metabolic Disease
PSEC13 is an activator of HSF-1/DAF-16 axis. PSEC13 can upregulate heat shock proteins. PSEC13 can form hydrogen bonds with key residues in the HSP-16.2 active site. PSEC13 can be used to enhance proteostasis and extend lifespan through the modulation of HSP-16.2. PSEC13 could promote the nuclear translocation of daf-16, upgrading the proportion of intermediate. PSEC13 can be studied in research for aging and age-related diseases .

HY-B1455S

Clindamycin-d3 hydrochloride	Bacterial Antibiotic Parasite	Infection
Clindamycin-d₃ (hydrochloride) is the deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .

HY-E70628

Aspartic acid proteinase	Biochemical Assay Reagents	Others
Aspartic acid proteinase is a type of proteolytic enzyme, which is characterized by its action via two critical aspartic acid residues in the active site, which facilitate the hydrolysis of peptide bonds in proteins .

HY-162593

Tubulin inhibitor 45	Microtubule/Tubulin	Cancer
Tubulin inhibitor 45 (compound 5) is an inhibitor of tubulin protein active sites. Tubulin inhibitor 45 against MCF7 and HePG2 cancer cells with IC₅₀ values of 11 μM and 13 μM .

HY-12933

BIIB-028	HSP	Cancer
BIIB-028 is an orally active inhibitor for *heat shock protein* 90 (Hsp90)*. BIIB-028 targets the ATP-binding site* of Hsp90, disrupts the function of Hsp90, leads to the degradation of client proteins, that are crucial for cancer cell survival and proliferation .

HY-E70726

FYN Y531F Recombinant Human Active Protein Kinase	Src	Cancer
FYN Y531F Recombinant Human Active Protein Kinase is an oncogene that directly activated YANK2 through phosphorylation its Y110, and Fyn-mediated YANK2 phosphorylation at Y110 site promotes glioma growth by increasing its stability .

HY-134561

6-Amino-8-trifluoromethylphenanthridine 6A-8tFP	Prion Protein	Infection
6-Amino-8-trifluoromethylphenanthridine (6A-8tFP) is an antiprion agent and a derivative of 6-aminophenanthridine (HY-135189). It inhibits protein folding activity of the ribosome (PFAR) when used at a concentration of 150 μM.2 6A-8tFP directly competes with protein substrates for the ribosomal active site.

HY-P5323

Dabcyl-AGHDAHASET-Edans	Bacterial	Others
Dabcyl-AGHDAHASET-Edans is a biological active peptide. (This is a type I signal peptidase (SPase1) substrate peptide labeled with EDANS/ DABCYL FRET pair, and contains a crucial cleavage site derived from the C-terminal region of the Staphylococcus epidermidis pre-SceD protein. Abs/Em = 340/490 nm.)

HY-134136

Octanoyl Coenzyme A	Endogenous Metabolite	Others
Octanoyl coenzyme A is an enoyl-CoA hydratase binder. Octanoyl coenzyme A binds to the active site of enoyl-CoA hydratase, occupies the binding pocket for the fatty acid tail of the enzyme's substrate, and induces a conformational shift in a flexible protein loop via its longer octanoyl chain, forming an open channel leading to the inter-trimer gap .

HY-134136B

Octanoyl coenzyme A triammonium S-Octanoate-CoA triammonium; S-Octanoate-coenzyme A triammonium	Biochemical Assay Reagents	Others
Octanoyl coenzyme A triammonium is an enoyl-CoA hydratase binder. Octanoyl coenzyme A triammonium binds to the active site of enoyl-CoA hydratase, occupies the binding pocket for the fatty acid tail of the enzyme's substrate, and induces a conformational shift in a flexible protein loop via its longer octanoyl chain, forming an open channel leading to the inter-trimer gap .

HY-13240A

LY2886721 hydrochloride	Beta-secretase	Neurological Disease
LY2886721 hydrochloride is a potent, selective and orally active *beta-site* amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC₅₀ of 20.3 nM for recombinant human BACE1. LY2886721 hydrochloride is selectivity against cathepsin D, pepsin, and renin, but lacking selectivity against BACE2 (IC₅₀** of 10.2 nM). LY2886721 hydrochloride can across blood-brain barrier and has the potential for Alzheimer's disease treatment .

HY-128774

AM-6494	Beta-secretase	Neurological Disease
AM-6494 is a potent and orally active BACE1 (efficacious β-site amyloid precursor protein cleaving enzyme 1) inhibitor (IC₅₀=0.4 nM) with in vivo selectivity over BACE2 (IC₅₀=18.6 nM) . AM-6494 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-W284558S

Sodium hexadecyl sulfate-d33	Isotope-Labeled Compounds Biochemical Assay Reagents	Others
Sodium hexadecyl sulfate-d₃₃ is the deuterium labeled Sodium hexadecyl sulfate. Sodium hexadecyl sulfate is a long-chain anionic surfactant. Sodium hexadecyl sulfate can act as an interface-regulating substance to form a soft layer on the surface of carbon nanotubes, guide proteins to adsorb in the correct orientation with active sites facing outward through electrostatic interactions, and significantly enhance the activity of immobilized enzymes. Sodium hexadecyl sulfate can replace or supplement SDS (HY-Y0316) in capillary gel electrophoresis (CGE) .

HY-P5395

TAT-GluR23A Fusion Peptide	HIV	Others
TAT-GluR23A Fusion Peptide is a biological active peptide. (This is the GluR23A sequence, a control inactive peptide used as a mutant counterpart to glutamate receptor endocytosis inhibitor (GluR23Y), connected to an 11 amino acid cell permeable HIV Trans-Activator of Transcription (TAT) protein transduction domain (PTD). GluR23A is derived from GluR23Y amino acids 869 to 877, with Ala substituted for Tyr, and thus lacking essential phosphorylation sites.Control peptide of HY-P2259)

HY-12770R

Mebeverine alcohol (Standard) Mebeverine metabolite Mebeverine alcohol (Standard)	Reference Standards Drug Metabolite	Neurological Disease
Mebeverine alcohol (Standard) is an analytical standard for Mebeverine alcohol. This product is intended for research and analytical applications. Eperezolid (PNU-100592) is an orally active protein synthesis inhibitor that targets the bacterial 50S ribosomal subunit. Eperezolid competitively binds to a specific site on the ribosomal 50S subunit (overlapping with the binding sites of Chloramphenicol (HY-B0239) and Lincomycin (HY-117660)) to inhibit the translation initiation stage and exert antibacterial activity. Eperezolid can induce host cell autophagy to enhance the clearance of intracellular mycobacteria, and its MIC90 for Staphylococcus aureus and Enterococcus is 1-4 μg/mL. Eperezolid is mainly used for antibacterial research on infections with Gram-positive bacteria such as methicillin-resistant (HY-121544) Staphylococci and vancomycin-resistant (HY-B0671) Enterococci, as well as infections with intracellular bacteria such as Mycobacterium tuberculosis .

HY-B1455R

Clindamycin (Standard)	Reference Standards Bacterial Antibiotic Parasite	Infection Cancer
Clindamycin (Standard) is the analytical standard of Clindamycin. This product is intended for research and analytical applications. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit *bacterial protein* synthesis*, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus* at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .

HY-156735

HSD17B13-IN-2	17β-HSD	Cancer
HSD17B13-IN-2 is an HSD17B13 inhibitor with human IC₅₀ values of 0.18 μM (with β-estradiol as substrate) and 0.25 μM (with Leukotriene B4 as substrate), and it exhibits selectivity for human HSD17B11. HSD17B13-IN-2 binds to the active site of HSD17B13 in an NAD ⁺-dependent manner, interacts with the bound NAD ⁺ cofactor, and stabilizes human HSD17B13 protein to prevent its aggregation. HSD17B13-IN-2 reduces the conversion of β-estradiol to estrone in cellular assays. HSD17B13-IN-2 can be used in studies related to nonalcoholic fatty liver disease .

HY-105517

MDL 27032	PKC PKA	Cardiovascular Disease
MDL 27032 is an active site-directed inhibitor of protein kinase C (PKC) and *cAMP-dependent protein* kinase (PKA) with K_i** values of 24 and 14.3μM. MDL 27032 can relaxe vascular smooth muscle and can be used as vasodilator .

HY-183291

Antibacterial agent 343	Bacterial DNA/RNA Synthesis DNA Alkylator/Crosslinker Reactive Oxygen Species (ROS) Penicillin-binding protein (PBP)	Infection
Antibacterial agent 343 (Compound 47) is an Antibacterial agent. Antibacterial agent 343 binds to the allosteric site of PBP2a to open its active site. Antibacterial agent 343 disrupts bacterial cell membranes, leading to protein leakage. Antibacterial agent 343 interacts with DNA and inhibits replication and transcription. Antibacterial agent 343 induces ROS accumulation. Antibacterial agent 343 exhibits antibacterial activity against MRSA, Staphylococcus aureus, and Enterococcus faecalis. Antibacterial agent 343 can be used for the research of methicillin-resistant Staphylococcus aureus infections .

HY-N19854

Mariaterpenoside A	NO Synthase	Neurological Disease
Mariaterpenoside A is an inducible nitric oxide synthase (iNOS) inhibitor. Mariaterpenoside A interacts with the active cavity of iNOS protein via hydrogen bonds with specific residues of the binding site. Mariaterpenoside A suppresses NO release in LPS (HY-D1056)-induced murine microglial BV-2 cells. Mariaterpenoside A can be used for the research of neurodegenerative disease .

HY-P2974A

Elastase, Rat	Elastase	Metabolic Disease
Elastase, Rat (EC 3.4.21.35) is a form of elastase that is produced in the acinar cells of the pancreas, initially produced as an inactive zymogen and later activated in the duodenum by trypsin. Elastases form a subfamily of serine proteases, characterized by a distinctive structure consisting of two beta-barrel domains converging at the active site that hydrolyze amides and esters amongst many proteins in addition to elastin, a type of connective tissue that holds organs together.

HY-W000854S

3-Methoxybenzeneboronic acid-d3 3-Methoxyphenylboronic acid-d₃	Isotope-Labeled Compounds	Others
3-Methoxybenzeneboronic acid-d₃ is the deuterium labeled 3-Methoxybenzeneboronic acid (HY-W000854). 3-Methoxybenzeneboronic acid (3-Methoxyphenylboronic acid) is a boronic acid derivative. 3-Methoxybenzeneboronic acid shows best suitable binding pattern at the active site by interacting non-covalently with amino acid residues of proteins. 3-Methoxybenzeneboronic acid is a biochemical reagent that can be used as a biological material or organic compound for life science related research .

HY-183698

CDK9-IN-51	CDK	Cancer
CDK9-IN-51 is a CDK9 inhibitor. CDK9-IN-51 binds stably to purified CDK9 protein via interactions with key active-site residues Cys106, Asp109, and Phe103. CDK9-IN-51 exhibits antiproliferative activity against multiple cancer cells. CDK9-IN-51 can be used for the research of cancer, such as lung carcinoma, cervical carcinoma and breast carcinoma .

HY-127083

Artecanin	SARS-CoV Virus Protease	Infection
Artecanin is a SARS-CoV-2 main protease (M ^pro) inhibitor with predicted high gastrointestinal absorption and oral bioavailability, and no predicted hepatotoxicity, carcinogenicity, mutagenicity or cytotoxicity. Artecanin interacts with His41 and Cys145, the key amino acid residues in the active site of M ^pro, blocks the cleavage and maturation of viral precursor proteins, and forms a stable complex with M ^pro. Artecanin blocks the invasion of SARS-CoV-2. Artecanin is applicable to the research of COVID-19 .

HY-183878

Zincov	Bacterial	Infection Metabolic Disease
Zincov is an orally active hydroxamic acid derivative and bacterial metalloproteinase inhibitor. Zincov blocks chloride ion binding by binding to the active site of thermolysin, thereby inhibiting the hydrolysis and blood coagulation reactions catalyzed by this enzyme. Meanwhile, Zincov attenuates cytotoxicity, prevents protein degradation and ZO-1 rearrangement without affecting the functions of other common proteases. Zincov exhibits blood glucose-regulating and antioxidant activities; it reduces blood glucose levels and increases liver dry weight in diabetic rats, but elevates blood glucose levels in normal rats. Zincov is widely used in studies related to cholera and diabetes .

Cat. No.	Product Name

HY-L918

Molecular Glue-like Compound Library

317 compounds

Targeted Protein Degradation (TPD) is a novel and promising approach to drug development. It shows great potential for targeting proteins traditionally considered "undruggable" due to the lack of enzymatic function and absence of binding sites by tagging them for degradation or recruiting natural degradation mechanisms.

Molecular glues are a type of small-molecule degraders that primarily induce novel interactions between E3 ubiquitin ligases and target proteins, forming ternary complexes that lead to protein ubiquitination and subsequent proteasomal degradation. Compared with PROTACs, molecular glues generally have lower molecular weights, higher cell permeability, and better drug-like properties. Additionally, the design of molecular glues is relatively simple, without the requirements for complex linkers and ligand optimization. As a result, molecular glues have gradually emerged as a promising therapeutic approach for various diseases.

Multiple types of molecular glues have been reported previously. Analysis of co-crystal complex structures reveals that CRBN-related molecular glues are more versatile. Therefore, MCE researchers select active molecules related to these targets as probes for artificial intelligence (AI) screening.Subsequently, molecular docking technology was used to verify whether the screened molecules retained the key pharmacophore features. Ultimately, we obtained 317 molecular glue analogs, and these compounds serve as powerful tools for the research of molecular glues.

HY-LD004

DEL Covalent Library

14 million compounds

DEL technology enables the simultaneous screening of millions or billions of compounds in a single tube by covalently linking each small molecule with a unique DNA sequence. Traditional DEL screening primarily focuses on identifying non-covalent binding molecules, where interactions with the target are reversible. In contrast, DNA‑encoded covalent library is an ultra‑high‑throughput screening library developed on the basis of conventional DNA‑encoded library technology. It incorporates controllable electrophilic covalent warheads capable of forming irreversible covalent bonds with amino acid residues at the active sites of target proteins, including Cys, Lys, Ser, Tyr, and others. This covalent binding enhances binding affinity, prolongs residence time at the target site, and has the potential to overcome challenges associated with traditional non-covalent inhibitors, such as drug resistance or off-target effects.

Each compound in the library contains both a binding domain and an electrophilic warhead. It first recognizes and binds to the target through non covalent interactions, and then forms a stable covalent bond with key amino acid residues to achieve irreversible inhibition. This library is specifically designed for the discovery of potent, long lasting, and highly selective covalent inhibitors, particularly for undruggable targets such as kinases, GPCRs, proteases, and mutant oncoproteins. Each molecule is uniquely labeled with a DNA barcode for molecular identification and sequencing decoding.

This library is an advanced and highly diverse collection, consists of 35 independent sub-libraries with a total scaleof 14 million compounds, It incorporates over 14 experimentally validated covalent warheads capable of targeting cysteine, lysine, arginine, aspartic acid and glutamic acid. This library is constructed with diverse drug like core scaffolds and integrated controllable covalent warheads, it features structural diversity, reaction spec

HY-L923

Ion Channel Lead-like Compound Library

9000 compounds

Ion channels are key proteins on the cell membrane that regulate the flow of ions across membranes. They participate in nearly all physiological processes, including nerve conduction, muscle contraction, heart rhythm, and pain perception. Abnormalities in their function can lead to various serious diseases such as arrhythmia, epilepsy, hypertension, neuropathic pain, and cancer. Therefore, ion channels are highly valuable drug targets—over 15% of approved drugs target ion channels currently, demonstrating their irreplaceable therapeutic value in cardiovascular, neurological, and analgesic fields.

MCE has collected a library of over 5,000 reported ion channel-related bioactive compounds targeting major sites such as Na+ channels, K+ channels, Ca2+ channels, GABA receptors, iGluRs, and others. Using AI models, these compounds are characterized through both 2D representations (molecular fingerprints, pharmacophores) and 3D representations (3D conformation) to screen for a collection of lead-like compounds highly similar to known active molecules. Additionally, an hERG channel prediction algorithm integrating XGB and ISE mapping strategy is employed to assess and exclude potential cardiotoxicity in the library.. This step significantly reduces safety risks in subsequent screenings, particularly for ion channel drug development related to cardiovascular systems (e.g., Nav1.5, Cav1.2), effectively minimizing failures due to hERG inhibition and serving as a valuable tool for ion channel drug screening.

Cat. No.	Product Name	Type

HY-W998680

Fluorescein-maleimide

5-FITC-Maleimide

Fluorescent Dyes

Fluorescein-maleimide (5-FITC-Maleimide) is a thiol-reactive fluorescent derivatization reagent and non-specific protein labeling reagent. Fluorescein-maleimide covalently binds to protein thiol groups for protein labeling. Fluorescein-maleimide covalently binds to protein amino and imidazole groups under neutral pH conditions. Fluorescein-maleimide is used for fluorescent labeling of proteins, nucleic acids or other molecules containing one or more thiol groups (Ex/Em = 494/519 nm) .

HY-D2956

BC-GLA-NHS

CLIP-GLA-NHS

Fluorescent Dyes

BC-GLA-NHS (CLIP-GLA-NHS) is a NHS-labeled CLIP tag, which is an amine-reactive crosslinker and can achieve site-specific protein labeling. The NHS ester of BC-GLA-NHS reacts with the primary amine of the target molecule (such as antibodies, quantum dots) in a pH 7.5-8.5 buffer solution to form a stable amide bond. After coupling, the BC molecule undergoes a nucleophilic substitution reaction with the active site (Cys) of the CLIP-tagged fusion protein, releasing benzylcytosine and forming an irreversible thioether bond, achieving covalent labeling. BC-GLA-NHS can be used for click chemistry labeling .

Cat. No.	Product Name	Type

HY-B2228

Proteinase, Aspergillus oryzae

1 Publications Verification

Biochemical Assay Reagents

Proteinase, Aspergillus oryzae is a serine protease that hydrolyzes peptide bonds in protein substrates, preferring alkaline conditions (optimal pH 10.5). It efficiently degrades casein, poly-L-glutamic acid, and poly-L-lysine, with activity irreversibly inhibited by diisopropylfluorophosphate (DFP) and potato inhibitor. This enzyme catalyzes proteolysis via serine residues in its active site, finding applications in food processing (e.g., soy sauce fermentation), detergents, and leather industries due to its high yield in solid-state fermentation and cost-effective production.

HY-15908

BCA 5+ Cited Publications Disodium bicinchoninate	Biochemical Assay Reagents
BCA (Disodium bicinchoninate) is an orally active and non-competitive *Beta-site* amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC₅₀ value of 28 µM, a K_i** value of 43 µM. BCA shows anticancer activity. BCA has the potential for the research of Alzheimer's disease (AD) .

HY-134136A

Octanoyl coenzyme A lithium	Biochemical Assay Reagents
Octanoyl coenzyme A lithium is an enoyl-CoA hydratase binder. Octanoyl coenzyme A lithium binds to the active site of enoyl-CoA hydratase, occupies the binding pocket for the fatty acid tail of the enzyme's substrate, and induces a conformational shift in a flexible protein loop via its longer octanoyl chain, forming an open channel leading to the inter-trimer gap .

HY-W284558

Sodium hexadecyl sulfate

Biochemical Assay Reagents

Sodium hexadecyl sulfate is a long-chain anionic surfactant. Sodium hexadecyl sulfate can act as an interface-regulating substance to form a soft layer on the surface of carbon nanotubes, guide proteins to adsorb in the correct orientation with active sites facing outward through electrostatic interactions, and significantly enhance the activity of immobilized enzymes. Sodium hexadecyl sulfate can replace or supplement SDS (HY-Y0316) in capillary gel electrophoresis (CGE) .

HY-W000854

3-Methoxybenzeneboronic acid 3-Methoxyphenylboronic acid	Biochemical Assay Reagents
3-Methoxybenzeneboronic acid (3-Methoxyphenylboronic acid) is a boronic acid derivative. 3-Methoxybenzeneboronic acid shows best suitable binding pattern at the active site by interacting non-covalently with amino acid residues of proteins. 3-Methoxybenzeneboronic acid is a biochemical reagent that can be used as a biological material or organic compound for life science related research .

HY-134136

Octanoyl Coenzyme A	Biochemical Assay Reagents
Octanoyl coenzyme A is an enoyl-CoA hydratase binder. Octanoyl coenzyme A binds to the active site of enoyl-CoA hydratase, occupies the binding pocket for the fatty acid tail of the enzyme's substrate, and induces a conformational shift in a flexible protein loop via its longer octanoyl chain, forming an open channel leading to the inter-trimer gap .

Cat. No.	Product Name	Target	Research Area

HY-P2463

Fequesetide	Arp2/3 Complex	Inflammation/Immunology
Fequesetide, a peptide segment, is the active site within the protein thymosin β₄ responsible for actin binding, cell migration and wound healing .

HY-P4508

SIGSLAK	Peptides	Others
SIGSLAK has the active site of E. coli penicillin-binding protein 1b .

HY-P5525

AC3-I, myristoylated Autocamtide-3 Derived Inhibitory Peptide	CaMK	Others
AC3-I, myristoylated is a biological active peptide. (This is a myristoylated form of Autocamtide-3-Derived Inhibitory Peptide (AC3-I), a highly specific inhibitor of Calmodulin-Dependent Protein Kinase ll (CaMKII) that is resistant to proteolysis. AC3-I is derived from Autocamtide-3, a substrate for CaMKII, with the Thr-9 phosphorylation site substituted with Ala.)

HY-P5323

Dabcyl-AGHDAHASET-Edans	Bacterial	Others
Dabcyl-AGHDAHASET-Edans is a biological active peptide. (This is a type I signal peptidase (SPase1) substrate peptide labeled with EDANS/ DABCYL FRET pair, and contains a crucial cleavage site derived from the C-terminal region of the Staphylococcus epidermidis pre-SceD protein. Abs/Em = 340/490 nm.)

HY-P5513

Aquaporin-2 (254-267), pSER261, human	Peptides	Others
Aquaporin-2 (254-267), pSER261, human is a biological active peptide. (This peptide is a fragment of the human aquaporin-2 (AQP2) phosphorylated at Ser261. Protein phosphorylation plays a key role in vasopressin signaling in renal-collecting duct. Phosphorylation at several AQP2 residues including Ser256 and Ser261, is altered in response to vasopressin. It is possible that both sites are involved in vasopressin-dependent AQP2 trafficking.)

HY-P5395

TAT-GluR23A Fusion Peptide	HIV	Others
TAT-GluR23A Fusion Peptide is a biological active peptide. (This is the GluR23A sequence, a control inactive peptide used as a mutant counterpart to glutamate receptor endocytosis inhibitor (GluR23Y), connected to an 11 amino acid cell permeable HIV Trans-Activator of Transcription (TAT) protein transduction domain (PTD). GluR23A is derived from GluR23Y amino acids 869 to 877, with Ala substituted for Tyr, and thus lacking essential phosphorylation sites.Control peptide of HY-P2259)

HY-P5466

S6(229-239)	Peptides	Others
S6(229-239) is a biological active peptide. (This is a synthetic peptide substrate for S6 kinase shown to be phosphorylated by protein kinase c with phosphorylation site identified at Ser235)

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N19854

Mariaterpenoside A	Structural Classification Glycine soya Plants Compositae Saccharides Monosaccharides Source Classification	NO Synthase
Mariaterpenoside A is an inducible nitric oxide synthase (iNOS) inhibitor. Mariaterpenoside A interacts with the active cavity of iNOS protein via hydrogen bonds with specific residues of the binding site. Mariaterpenoside A suppresses NO release in LPS (HY-D1056)-induced murine microglial BV-2 cells. Mariaterpenoside A can be used for the research of neurodegenerative disease .

HY-127083

Artecanin	Structural Classification Natural Products Laurus nobilis L. Plants Lauraceae Source Classification	SARS-CoV Virus Protease
Artecanin is a SARS-CoV-2 main protease (M ^pro) inhibitor with predicted high gastrointestinal absorption and oral bioavailability, and no predicted hepatotoxicity, carcinogenicity, mutagenicity or cytotoxicity. Artecanin interacts with His41 and Cys145, the key amino acid residues in the active site of M ^pro, blocks the cleavage and maturation of viral precursor proteins, and forms a stable complex with M ^pro. Artecanin blocks the invasion of SARS-CoV-2. Artecanin is applicable to the research of COVID-19 .

Cat. No.	Product Name	Chemical Structure

HY-B1455S1

Clindamycin-13C,d3

Clindamycin- ¹³C,d₃ is the ¹³C- and deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .

HY-B1455S

Clindamycin-d3 hydrochloride

Clindamycin-d₃ (hydrochloride) is the deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .

HY-W284558S

Sodium hexadecyl sulfate-d33

Sodium hexadecyl sulfate-d₃₃ is the deuterium labeled Sodium hexadecyl sulfate. Sodium hexadecyl sulfate is a long-chain anionic surfactant. Sodium hexadecyl sulfate can act as an interface-regulating substance to form a soft layer on the surface of carbon nanotubes, guide proteins to adsorb in the correct orientation with active sites facing outward through electrostatic interactions, and significantly enhance the activity of immobilized enzymes. Sodium hexadecyl sulfate can replace or supplement SDS (HY-Y0316) in capillary gel electrophoresis (CGE) .

HY-W000854S

3-Methoxybenzeneboronic acid-d3

3-Methoxybenzeneboronic acid-d₃ is the deuterium labeled 3-Methoxybenzeneboronic acid (HY-W000854). 3-Methoxybenzeneboronic acid (3-Methoxyphenylboronic acid) is a boronic acid derivative. 3-Methoxybenzeneboronic acid shows best suitable binding pattern at the active site by interacting non-covalently with amino acid residues of proteins. 3-Methoxybenzeneboronic acid is a biochemical reagent that can be used as a biological material or organic compound for life science related research .

Cat. No.	Product Name		Classification

HY-100433

PACMA 31 5 Publications Verification		Alkynes
PACMA 31 is an irreversible, orally active protein disulfide isomerase (PDI) inhibitor with an IC₅₀ of 10 μM. PACMA 31 forms a covalent bond with the active site cysteines of PDI. PACMA 31 shows tumor targeting ability and significantly suppresses ovarian tumor growth without causing toxicity to normal tissues . PACMA 31 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-142035

N-Propargylglycine 1 Publications Verification		Alkynes
N-Propargylglycine is a brain-penetrant and orally active PRODH inhibitor. N-Propargylglycine covalently modifies enzyme-bound FAD and active site lysine, causing enzyme structural distortion, protein decay, and irreversible inhibition of proline and 4-hydroxyproline catabolism. N-Propargylglycine induces UPRmt, upregulates mitochondrial chaperones and YME1L1, enhances mitochondrial proteostasis, blocks astrocytic L-proline consumption, and abolishes L-proline’s ATP-maintaining and viability-protective effects. N-Propargylglycine stimulates neural processes, increases brain proline, hydroxyproline, and sarcosine levels, partially normalizes Huntington’s disease whole brain transcriptomes. N-Propargylglycine reduces hyperoxaluria, prevents calcium oxalate stone formation, reduces kidney tubular damage, and restores weight and survival in Grhpr knockout mice. N-Propargylglycine can be used for the research of breast cancer, neurodegenerative disorders, Huntington’s disease, and primary hyperoxaluria type 2 .

HY-128774

AM-6494		Alkynes
AM-6494 is a potent and orally active BACE1 (efficacious β-site amyloid precursor protein cleaving enzyme 1) inhibitor (IC₅₀=0.4 nM) with in vivo selectivity over BACE2 (IC₅₀=18.6 nM) . AM-6494 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

protein active sites

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products